Size: | Price | Quantity | |
---|---|---|---|
5 mg | $80.00 | ||
25 mg | $300.00 |
Crizotinib (877399-52-5) is a potent and selective inhibitor of c-MET and ALK, IC50‘s=8 and 20 nM respectively.1 Inhibition of cell proliferation was associated with G1-S phase cell cycle arrest and induction of apoptosis in ALK-positive ALCL cells (IC50=30 nM) but not in ALK-negative lymphoma cells.1 Exhibits cytoreductive antitumor efficacy via antiproliferative and antiangiogenic mechanisms.2 Clinically useful anticancer agent.3
References/Citations:
1) Christensen et al. (2007), Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma; Mol. Cancer Ther., 6 3314
2) Zou et al. (2007), An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms; Cancer Res., 67 4408
3) Bang et al. (2010), Clinical activity of the oral ALK inhibitor PF-02341066 in ALK-positive patients with non-small cell lung cancer (NSCLC); J. Clin. Oncol., 28 3
Materials provided by Focus Biomolecules are for laboratory research use only and are not intended for human or veterinary applications. Please note that we do not sell to individuals and that all orders placed by non-research organizations will incur a $20 restocking/refund fee
Crizotinib (877399-52-5) is a potent and selective inhibitor of c-MET and ALK, IC50‘s=8 and 20 nM respectively.1 Inhibition of cell proliferation was associated with G1-S phase cell cycle arrest and induction of apoptosis in ALK-positive ALCL cells (IC50=30 nM) but not in ALK-negative lymphoma cells.1 Exhibits cytoreductive antitumor efficacy via antiproliferative and antiangiogenic mechanisms.2 Clinically useful anticancer agent.3
References/Citations:
1) Christensen et al. (2007), Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma; Mol. Cancer Ther., 6 3314
2) Zou et al. (2007), An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms; Cancer Res., 67 4408
3) Bang et al. (2010), Clinical activity of the oral ALK inhibitor PF-02341066 in ALK-positive patients with non-small cell lung cancer (NSCLC); J. Clin. Oncol., 28 3
Calculate the molar concentration, mass or volume in a solution.
Concentration × Volume × Molecular Weight = Mass
For Postdoc
Customers!
Website Created by Advanta Advertising LLC.